Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations
No abstract available (Source: Transplantation)
Source: Transplantation - September 1, 2015 Category: Transplant Surgery Tags: Letters Source Type: research
Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
Conclusions: Our results indicated a reversible increase in RBV bioavailability after telaprevir exposure, which might be linked to the impairment of the GFR. This also suggests a RBV-telaprevir pharmacological interaction, a possible source of severe anemia observed under triple therapy. These results suggest that RBV pharmacological monitoring may be clinically relevant, especially in the context of first-generation HCV protease inhibitor-based therapy.,Background: Anemia is more frequent in patients receiving telaprevir with PEGylated interferon/ribavirin (PEG-IFN/RBV) than in those receiving PEG-IFN/RBV alone.,Objectiv...
Source: Hepatitis Monthly - August 31, 2015 Category: Infectious Diseases Source Type: research
Randomized trials of ombitasvir/paritaprevir/r+dasabuvir±ribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV
Telaprevir plus peginterferon/ribavirin(TPV+pegIFN/RBV) remains a therapeutic option for chronic HCV genotype(GT) 1 infection in many regions. We conducted two open-label, phase 3b trials comparing safety and efficacy of all-oral ombitasvir/paritaprevir/ritonavir and dasabuvir+/-ribavirin(OBV/PTV/r+DSV+/-RBV) and TPV+pegIFN/RBV. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 27, 2015 Category: Gastroenterology Authors: Gregory J. Dore, Brian Conway, Yan Luo, Ewa Janczewska, Brygida Knysz, Yan Liu, Adrian Streinu-Cercel, Florin Alexandru Caruntu, Manuela Curescu, Richard Skoien, Wayne Ghesquiere, Włodzimierz Mazur, Alejandro Soza, Francisco Fuster, Susan Greenbloom, Adr Source Type: research
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Telaprevir plus pegylated interferon/ribavirin (TPV+PegIFN/RBV) remains a therapeutic option for chronic hepatitis C virus (HCV) genotype (GT) 1 infection in many regions. We conducted two open-label, phase IIIb trials comparing safety and efficacy of all-oral ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin (OBV/PTV/r+DSV±RBV) and TPV+PegIFN/RBV. (Source: Journal of Hepatology)
Source: Journal of Hepatology - August 27, 2015 Category: Gastroenterology Authors: Gregory J. Dore, Brian Conway, Yan Luo, Ewa Janczewska, Brygida Knysz, Yan Liu, Adrian Streinu-Cercel, Florin Alexandru Caruntu, Manuela Curescu, Richard Skoien, Wayne Ghesquiere, Włodzimierz Mazur, Alejandro Soza, Francisco Fuster, Susan Greenbloom, Adr Tags: Research Article Source Type: research
Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician
Not since the late 1990s with the arrival of highly active anti-retroviral therapy for HIV has there been such an explosion of new compounds and regimens in the field of virology. The slow beginnings of this new era, the direct-acting antiviral (DAA) therapy for hepatitis C, started a few years ago with the first protease inhibitors, boceprevir and telaprevir, each being paired with interferon and ribavirin, leading to a significant improvement in response rates, but only in the easiest-to-cure population of treatment-naïve patients with genotype 1 virus. (Source: Clinics in Liver Disease)
Source: Clinics in Liver Disease - August 26, 2015 Category: Gastroenterology Authors: Fred Poordad Tags: Preface Source Type: research
UPLC–MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells
Publication date: 10 November 2015 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 115 Author(s): Amedeo De Nicolò, Adnan Mohamed Abdi, Lucio Boglione, Lorena Baiett, Sarah Allegra, Giovanni Di Perri, Antonio D’Avolio HCV infection affects over 170 million people worldwide. The current standard for treatment of genotype 1 infection is the association of the first generation protease inhibitors boceprevir or telaprevir to ribavirin and peginterferon α. Although the response rate has been improved with these new drugs, some pharmacokinetic/pharmacodinamic issues emerged in the past year...
Source: Journal of Pharmaceutical and Biomedical Analysis - August 25, 2015 Category: Drugs & Pharmacology Source Type: research
Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies
Abstract
Viral dynamic modelling has proven useful for designing clinical studies and predicting treatment outcomes for patients infected with the hepatitis C virus. Generally these models aim to capture and predict the on-treatment viral load dynamics from a small study of individual patients. Here, we explored extending these models (1) to clinical studies with numerous patients and (2) by incorporating additional data types, including sequence data and prior response to interferon. Data from Phase 3 clinical studies of the direct-acting antiviral telaprevir (T; total daily dose of 2250 mg) combined wi...
Source: Journal of Pharmacokinetics and Pharmacodynamics - August 19, 2015 Category: Drugs & Pharmacology Source Type: research
Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
ConclusionsCost‐effectiveness conclusions are similar for patients treated in the chronic hepatitis C and CC disease stages, with DCV+ASV expected to be cost‐saving versus standard of care in Japan for patients with HCV genotype 1b patients that failed prior therapy or are interferon‐ineligible/intolerant. This article is protected by copyright. All rights reserved. (Source: Hepatology Research)
Source: Hepatology Research - August 19, 2015 Category: Internal Medicine Authors: Phil McEwan, Thomas Ward, Samantha Webster, Yong Yuan, Anupama Kalsekar, Isao Kamae, Masahiro Kobayashi, Ann Tang, Hiromitsu Kumada Tags: Original Article Source Type: research
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
CONCLUSION: In a real clinical practice setting with a high proportion of patients with advanced fibrosis, effectiveness of first-generation PIs was high except for NR patients, with similar SVR rates being achieved by BOC and TVR.
PMID: 26290644 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - August 14, 2015 Category: Gastroenterology Authors: Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernánde Tags: World J Gastroenterol Source Type: research
Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents
Purpose of review: Liver transplantation is widely used to treat HIV patients with an end-stage liver disease, mainly decompensated cirrhosis and hepatocellular carcinoma. The results are good especially in non-hepatitis C virus (HCV)-coinfected patients. In HIV–HCV-coinfected patients, 5-year post-liver transplantation survival is around 50–55%, negatively impacted by HCV recurrence. The results of PEG-IFN/RBV are poor in terms of efficacy and safety. In patients with genotype 1 infection, triple therapy (boceprevir or telaprevir) has increased sustained virological response (SVR) rate, but drug–drug interactions (D...
Source: Current Opinion in HIV and AIDS - August 7, 2015 Category: Infectious Diseases Tags: HCV DIRECT ANTIVIRAL AGENTS IN HIV: Edited by Karine Lacombe and Sanjay R. Bhagani Source Type: research
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese HCV patients
ConclusionMarked differences were observed in the efficacy and safety profile of daclatasvir in combination with asunaprevir, compared with telaprevir plus peginterferon/ribavirin. This article is protected by copyright. All rights reserved. (Source: Journal of Gastroenterology and Hepatology)
Source: Journal of Gastroenterology and Hepatology - August 7, 2015 Category: Gastroenterology Authors: Hiromitsu Kumada, Fumitaka Suzuki, Yoshiyuki Suzuki, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Shigetoshi Fujiyama, Takayoshi Ito, Yoshito Itoh, Etsuko Tamura, Tomoko Ueki, Hiroki Ishikawa, Wenhua Hu, Fiona McPhee, Misti Linaberry Tags: Clinical Trials and Therapeutics Source Type: research
Anti-hepatitis C virus activity of a crude extract from longan (Dimocarpus longan Lour.) leaves.
In this study, we examined the antiviral activity of a crude extract from Dimocarpus longan leaves against HCV (genotype 2a strain JFH1). The D. longan crude extract exhibited anti-HCV activity with a 50% effective concentration (EC50) of 19.4 μg/ml without cytotoxicity. A time-of-addition study demonstrated that the crude extract exerts anti-HCV activity at both the entry and post-entry steps. The crude extract markedly blocked viral entry step through a direct virucidal effect with a marginal inhibition of virion assembly. The co-treatment of the crude extract with cyclosporine A or telaprevir, an NS3 protease inhibitor...
Source: Japanese Journal of Infectious Diseases - August 7, 2015 Category: Infectious Diseases Authors: Apriyanto DR, Aoki C, Hartati S, Hanafi M, Kardono LB, Arsianti A, Louisa M, Sudiro TM, Dewi BE, Sudarmono P, Soebandrio A, Hotta H Tags: Jpn J Infect Dis Source Type: research
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Conclusions:
For genotype 1, sofosbuvir-based treatments are not cost-effective compared to Viekira Pak and Harvoni, although a 30 % reduction in sofosbuvir price would change this result. Sofosbuvir + ribavirin are cost-effective as second-phase treatments following peginterferon + ribavirin initial treatment for genotypes 2 and 3. However, there is limited data on sofosbuvir-involved treatment, and the results obtained in this study must be interpreted within the model assumptions. (Source: BMC Gastroenterology)
Source: BMC Gastroenterology - August 5, 2015 Category: Gastroenterology Authors: Sai ZhangNathaniel BastianPaul Griffin Source Type: research
Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF‐κB‐ and MAPK‐ERK1/2‐mediated COX‐2 expression
Conclusions and ImplicationsBA inhibits HCV replication by suppressing the NF‐κB‐ and ERK1/2‐mediated COX‐2 pathway and may serve as a promising compound for drug development or as a potential supplement for use in the treatment of HCV‐infected patients. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - August 3, 2015 Category: Drugs & Pharmacology Authors: Chun‐Kuang Lin, Chin‐Kai Tseng, Kai‐Hsun Chen, Shih‐Hsiung Wu, Chih‐Chuang Liaw, Jin‐Ching Lee Tags: RESEARCH PAPER Source Type: research
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study
Conclusions: For LT recipients with recurrent advanced HCV and at greatest need of cure, protease inhibitor–based triple therapy achieved approximately 50% SVR12. However, there is significant risk of serious adverse events, arguing for earlier intervention. The availability of treatments with better efficacy and safety is of particular importance for posttransplant patients with advanced disease. (Source: Transplantation)
Source: Transplantation - August 1, 2015 Category: Transplant Surgery Tags: Original Clinical Science-Liver Source Type: research
